{
    "id": "63892796",
    "text": "Lutetium (177Lu) chloride, sold under the brand name Lumark among others, is a radioactive compound used for radiolabeling other medicines. Text was copied from this source which is \u00a9 European Medicines Agency. Reproduction is authorized provided the source is acknowledged. Text was copied from this source which is \u00a9 European Medicines Agency. Reproduction is authorized provided the source is acknowledged. The most common side effects are anaemia (low red blood cell counts), thrombocytopenia (low blood platelet counts), leucopenia (low white blood cell counts), lymphopenia (low levels of lymphocytes, a particular type of white blood cell), nausea (feeling sick), vomiting and mild and temporary hair loss. == Medical uses == Lutetium (177Lu) chloride is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabeling of carrier molecules that have been specifically developed and authorised for radiolabeling with Lutetium (177Lu) chloride. == Contraindications == Medicines radiolabeled with lutetium (177Lu) chloride must not be used in women unless pregnancy has been ruled out. == History == Lutetium (177Lu) chloride (Lumark) was approved for use in the European Union in June 2015. Lutetium (177Lu) chloride (EndolucinBeta) was approved for use in the European Union in July 2016. ==See also== * Lutetium(III) chloride == References == ==External links== * Category:Radiopharmaceuticals Category:Lutetium compounds Category:Chlorides ",
    "title": "Lutetium (177Lu) chloride"
}